Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tyrian Restructures Its Operations
The company has reduced its headcount by 17 since June 2008, from 42 to 25, including the closure of its therapeutics business in Boston. This is the end
The company has reduced its headcount by 17 since June 2008, from 42 to 25, including the closure of its therapeutics business in Boston. This is the end
Investors will also receive warrants to purchase 14.22 million shares of Avi BioPharma common stock. The closing of the offering is expected to take place on January 30,
Mylan has been awarded 180 days of marketing exclusivity for the 500mg strength, which it will begin to ship February 2, 2009. Mylan was the first company to
Mr Pauli has been CFO of OctoPlus since January 1, 2003. The executive board will aim to fill the vacancy of CFO as soon as possible. Simon Sturge,
The committee consists of John Kapoor, chairman of the board of directors and directors Randall Wall and Jerry Ellis. Dr Kapoor said: “Our current management team will execute
Under the agreement, Fujirebio Diagnostics will develop and manufacture for Abbott the HE4 biomarker, a simple blood test that may help in the risk stratification of women at
Prior to joining Synergetics, Mr Hable served as president and CEO of Afferent, a venture capital backed medical device company focused on neuro stimulation therapies. Previously, Mr Hable
Based on the special protocol assessment agreement (SPA), Inspire has initiated a Phase III, randomized, placebo-controlled, environmental clinical trial to evaluate the efficacy and safety of Prolacria in
Under the terms of this financing, investments will be made in three tranches: $12 million before March 31, 2009, $12 million before December 31, 2009 and $12 million
The AdnaTest diagnostic and analytical products for breast and colon cancer are aimed at improving cancer prognosis and patient management. The tests are based on immunomagnetic selection of